Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
P/B ratio for Immunovant, Inc. (IMVT)
P/B ratio as of 2024: 7.07
According to Immunovant, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.07. At the end of 2023 the company had a P/B ratio of 5.27.
P/B ratio history for Immunovant, Inc. from 2018 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | 7.07 |
| 2023 | 5.27 |
| 2022 | 1.29 |
| 2021 | 3.60 |
| 2020 | 7.15 |
| 2019 | 5825.65 |
| 2018 | -66.47 |